fasttrack
diagnost
respiratori
pathogen
ftdrp
multiplex
realtim
rtpcr
assay
compar
inhous
singleplex
realtim
rtpcr
assay
detect
common
respiratori
virus
ftdrp
assay
correctli
identifi
divers
respiratori
viru
strain
extern
qualiti
assess
sampl
spike
cultur
viru
archiv
respiratori
specimen
test
posit
respiratori
virus
inhous
assay
prospect
test
respiratori
specimen
select
children
hospit
acut
respiratori
ill
posit
ftdrp
inhous
assay
one
virus
respect
combin
test
result
show
good
concord
k
ci
individu
ftdrp
assay
adenoviru
respiratori
syncyti
viru
rhinoviru
show
lowest
compar
sensit
inhous
assay
discrep
occur
specimen
contain
low
viru
load
fail
detect
rhinoviru
strain
even
abund
ftdrp
enteroviru
human
bocaviru
assay
appear
sensit
inhous
assay
specimen
except
note
ftdrp
assay
perform
compar
inhous
assay
virus
offer
enhanc
throughput
easi
integr
laboratori
use
convent
realtim
pcr
instrument
publish
elsevi
bv
respiratori
virus
among
import
caus
human
morbid
mortal
worldwid
nair
et
al
pavia
clinic
indistinguish
respiratori
viru
infect
requir
accur
laboratori
diagnosi
guid
treatment
effect
prevent
decis
polymeras
chain
reaction
pcr
molecular
assay
routin
use
diagnosi
content
manuscript
sole
respons
author
necessarili
repres
offici
view
us
center
diseas
control
prevent
cdc
depart
health
human
servic
dhh
name
specif
vendor
manufactur
product
includ
public
health
inform
purpos
inclus
impli
endors
vendor
manufactur
product
cdc
dhh
respiratori
viru
infect
beck
henrickson
kehl
kumar
larg
increas
number
virus
make
laboratori
test
individu
singleplex
viru
assay
challeng
convers
multiplex
pcr
assay
combin
multipl
individu
assay
singl
reaction
facilit
rapid
high
throughput
costeffect
test
gener
prefer
clinic
set
elnifro
et
al
jansen
et
al
numer
laboratorydevelop
commerci
multiplex
pcr
assay
use
differ
amplif
platform
describ
respiratori
virus
gener
shown
superior
tradit
diagnost
method
viru
cultur
antigen
detect
sensit
specif
detect
respiratori
virus
aren
et
al
bibbi
et
al
brittainlong
et
al
caliendo
gadsbi
et
al
kim
et
al
lamson
et
al
mahoni
et
al
raymond
et
al
us
food
drug
administr
fda
clear
recent
two
commerci
assay
xtag
rvp
fast
luminex
molecular
diagnost
austin
tx
filmarray
respiratori
panel
idaho
technolog
inc
salt
lake
citi
utah
rand
et
al
invitro
diagnost
use
multiplex
detect
respiratori
virus
howev
mani
assay
costli
requir
special
laboratori
equip
use
highli
multiplex
reaction
may
defici
individu
assay
perform
difficult
modifi
without
extens
assay
reoptim
gunson
et
al
ftd
respiratori
pathogen
ftdrp
multiplex
assay
kit
fasttrack
diagnost
luxembourg
use
standard
commerci
onestep
revers
transcript
rt
pcr
hydrolysi
probe
chemistri
common
realtim
pcr
instrument
ftdrp
assay
consist
discret
primerprob
mix
togeth
cover
common
human
respiratori
virus
studi
report
result
comparison
ftdrp
multiplex
assay
panel
valid
inhous
singleplex
realtim
rtpcr
assay
develop
center
diseas
control
prevent
cdc
viru
isol
archiv
clinic
specimen
obtain
cdc
collect
acquir
routin
surveil
outbreak
investig
includ
laboratori
refer
viru
strain
field
isol
geograph
us
central
south
america
africa
composit
divers
specimen
nasopharyng
oropharyng
swab
nasal
wash
aspir
sputum
lung
autopsi
tissu
unidentifi
collect
children
adult
acut
respiratori
ill
ari
acquir
previous
test
posit
respiratori
virus
inhous
singleplex
assay
residu
sampl
extract
store
c
whenev
possibl
archiv
specimen
select
achiev
proport
represent
viral
load
fortysix
mock
human
specimen
spike
moderatetolow
concentr
viru
avail
qualiti
control
molecular
diagnost
qcmd
glasgow
scotland
extern
qualiti
assess
eqa
program
rhinoviruscoronaviru
adenoviru
parainfluenza
virus
human
metapneumovirusrespiratori
syncyti
viru
influenza
b
virus
wallac
pool
nasal
wash
specimen
consent
healthi
new
militari
recruit
kindli
provid
dr
lisa
lott
eagl
appli
scienc
llc
san
antonio
tx
final
subset
nasopharyng
aspir
npa
etiolog
studi
children
year
age
hospit
ari
tertiari
hospit
paulo
brazil
march
septemb
select
season
peak
respiratori
viru
circul
studi
year
base
local
surveil
data
npa
collect
directli
liquid
nitrogen
aliquot
transfer
c
retain
retriev
studi
studi
approv
institut
review
board
univers
paulo
santa
casa
de
de
paulo
hospit
brazil
cdc
total
nucleic
acid
tna
extract
prepar
sampl
use
nuclisen
easymag
multipl
studi
origin
test
histori
residu
archiv
specimen
extract
volum
vari
l
tna
elut
volum
l
rnasefre
water
ad
archiv
extract
dilut
obtain
suffici
volum
comparison
test
prospect
test
nasal
aspir
specimen
l
sampl
extract
tna
recov
l
elut
buffer
split
aliquot
frozen
c
test
extract
subject
ident
freezethaw
cycl
comparison
test
extract
confirm
posit
human
rnase
p
gene
realtim
rtpcr
inclus
studi
ftdrp
multiplex
realtim
rtpcr
assay
cat
ftd
consist
separ
primerprob
mix
cover
human
respiratori
virus
brome
mosaic
viru
bmv
rna
plant
viru
serv
intern
extract
control
spike
sampl
viru
provid
mix
influenza
viru
inf
influenza
b
viru
inf
b
bmv
mix
coronaviru
cov
enterovirusparechoviru
evpev
mix
parainfluenza
viru
piv
mix
piv
human
metapneumoviru
hmpv
human
bocaviru
hbov
mix
rhinoviru
rv
respiratori
syncyti
viru
rsv
adenoviru
adv
individu
assay
within
pool
distinguish
use
differ
probe
fluorophor
except
ev
pev
assay
probe
roxlabel
therefor
distinguish
kit
also
contain
posit
plasmid
control
pool
detail
instruct
test
perform
ftdrp
assay
perform
follow
manufactur
recommend
briefli
l
rtpcr
buffer
combin
l
primerprob
pool
l
enzym
mix
agpathid
tm
onestep
rtpcr
kit
appli
biosystem
l
mixtur
ad
well
pcr
plate
sampl
reaction
plu
one
posit
one
neg
viru
control
ten
l
sampl
tna
extract
control
ad
respect
well
primerprob
pool
follow
cycl
condit
perform
fast
dx
realtim
pcr
instrument
appli
biosystem
min
c
min
c
cycl
c
c
threshold
cycl
ct
valu
determin
manual
adjust
fluoresc
baselin
fall
within
exponenti
phase
amplif
curv
background
signal
posit
test
result
consid
welldefin
curv
cross
threshold
cycl
within
cycl
posit
neg
viru
plasmid
control
provid
kit
includ
run
monitor
assay
perform
bmv
intern
control
spike
clinic
specimen
monitor
sampl
extract
revers
transcript
previous
extract
tna
sampl
evalu
rnase
p
inhous
singleplex
realtim
rtpcr
assay
rsv
hmpv
rv
adv
hbov
cov
sarscov
previous
describ
dare
et
al
emeri
et
al
fri
et
al
heim
et
al
kodani
et
al
lu
et
al
lu
et
al
morgan
et
al
perform
qpcr
system
agil
technolog
use
agpathid
tm
onestep
rtpcr
reagent
appli
biosystem
follow
cycl
condit
c
min
c
min
cycl
c
c
min
primerprob
sequenc
avail
de
request
inhous
ev
pev
assay
modifi
previou
report
kilpatrick
et
al
nix
et
al
perform
qpcr
system
use
superscript
iii
platinum
onestep
quantit
rtpcr
system
reagent
invitrogen
follow
cycl
condit
c
min
c
min
cycl
c
c
ev
c
pev
c
univers
inf
inf
b
assay
perform
fast
dx
realtim
pcr
instrument
sd
softwar
ver
appli
biosystem
use
superscript
iii
platinum
onestep
quantit
rtpcr
system
follow
cycl
condit
c
min
c
min
cycl
c
c
stephen
lindstrom
cdc
person
commun
follow
standard
oper
procedur
inhous
assay
perform
l
final
reaction
volum
contain
l
sampl
tna
extract
posit
test
result
consid
welldefin
curv
cross
threshold
cycl
within
cycl
posit
neg
viru
rna
transcript
whole
viru
extract
control
includ
run
monitor
assay
perform
percent
sensit
specif
ftdrp
assay
prospect
collect
specimen
calcul
use
inhous
assay
refer
standard
agreement
assay
measur
use
kappa
statist
cohen
indic
agreement
indic
perfect
agreement
ftdrp
assay
first
evalu
undilut
tna
cultur
respiratori
viru
strain
correspond
assay
multiplex
assess
assay
specif
viru
strain
inclus
tabl
although
ftdrp
assay
sarscov
avail
viru
test
assess
specif
ftdrp
cov
assay
hbov
cov
isol
avail
test
posit
result
obtain
assay
virus
crossreact
detect
ftdrp
inhous
assay
result
within
valu
virus
test
notabl
ftdrp
rv
assay
gave
substanti
higher
ct
valu
one
rv
isol
serial
dilut
tna
show
ftdrp
assay
less
sensit
correspond
inhous
assay
viru
strain
data
shown
specif
ftdrp
assay
evalu
pool
nasal
wash
sampl
consent
normal
healthi
adult
repres
divers
microbi
flora
human
respiratori
tract
posit
result
obtain
inhous
assay
rv
ct
cov
ct
adv
ct
confirm
altern
rtpcr
assay
sequenc
ftdrp
assay
posit
rv
ct
cov
ct
detect
adv
initi
repeat
test
inhous
ftdrp
assay
neg
fortyon
mock
respiratori
sampl
spike
low
moder
level
differ
virus
neg
control
sampl
select
qcmd
eqa
program
hrvcov
adv
piv
rsvhmpv
inf
ab
test
assess
assay
perform
refer
qcmd
assay
tabl
overal
expect
result
obtain
posit
eqa
program
sampl
inhous
ftdrp
assay
respect
program
neg
control
sampl
neg
assay
one
sampl
low
concentr
initi
neg
inhous
assay
posit
repeat
test
ftdrp
assay
gave
expect
result
piv
cov
inf
tabl
comparison
ftdrp
inhous
assay
archiv
respiratori
specimen
previous
posit
respiratori
virus
inhous
assay
result
classifi
strong
ct
moder
ct
weak
ct
posit
c
ftdrp
evpev
assay
distinguish
ev
pev
eight
specimen
separ
test
posit
ev
pev
inhous
assay
comparison
ftdrp
inhous
assay
archiv
respiratori
specimen
sequenc
confirm
rhinoviru
rv
enteroviru
ev
consist
neg
show
substanti
higher
ct
valu
ftdrp
rv
assay
two
hundr
sixtyf
divers
respiratori
specimen
previous
test
posit
respiratori
virus
inhous
assay
select
comparison
ftdrp
assay
posit
least
one
assay
avail
ftdrp
multiplex
two
specimen
posit
cov
correspond
ftdrp
assay
also
test
assess
specif
ftdrp
cov
assay
tabl
limit
avail
sampl
volum
ftdrp
multiplex
mix
contain
virusspecif
assay
perform
viru
codetect
assay
multiplex
mix
includ
analysi
specimen
confirm
posit
inhous
singleplex
assay
retest
ftdrp
assay
identifi
specimen
posit
hbov
cov
inf
inf
b
hmpv
evpev
ev
pev
rv
rsv
adv
overal
ftdrp
assay
identifi
correctli
archiv
specimen
posit
respiratori
virus
inhous
assay
specimen
lower
ct
valu
two
specimen
posit
cov
inhous
singleplex
assay
neg
ftdrp
cov
assay
ftdrp
adv
rsv
rv
assay
gave
lowest
rel
sensit
archiv
specimen
respect
except
rv
discrep
occur
sampl
contain
low
level
viral
target
exampl
ftdrp
adv
falseneg
occur
moder
high
ct
valu
specimen
mean
ct
rang
appear
associ
particular
adv
type
wide
rang
sequenceconfirm
adv
type
repres
among
archiv
specimen
includ
speci
b
type
c
type
untyp
f
type
suggest
ftdrp
adv
assay
inclus
recogn
human
adv
type
contrast
ftdrp
rv
assay
fail
detect
rv
posit
sampl
low
ct
valu
correspond
inhous
assay
assess
ftdrp
rv
evpev
assay
viru
typestrain
inclus
group
exclus
archiv
sampl
high
rv
ev
load
type
partial
andor
rtpcr
sequenc
protocol
avail
xl
request
retest
tabl
ftdrp
rv
assay
gave
neg
result
sampl
valu
higher
inhous
assay
other
speci
b
c
rv
ftdrp
evpev
assay
also
posit
sequenceconfirm
rv
posit
specimen
also
posit
inhous
ev
assay
second
sampl
also
gave
exponenti
fluoresc
amplif
curv
inhous
ev
assay
valu
therefor
classifi
evneg
base
test
cutoff
criteria
although
ev
detect
sampl
rtpcr
pev
detect
inhous
assay
presenc
virus
could
rule
definit
nevertheless
probabl
explan
result
ftdrp
inhous
ev
assay
crossreact
rv
strain
five
sequenceconfirm
evposit
sampl
posit
ftdrp
evpev
assay
evid
crossreact
rv
pev
assay
three
hundredeight
nasopharyng
aspir
select
studi
infant
young
children
hospit
acut
respiratori
infect
test
prospect
inhous
ftdrp
assay
posit
one
virus
either
inhous
singleplex
ftdrp
multiplex
assay
posit
inhous
assay
posit
ftdrp
assay
alon
tabl
overal
inhous
ftdrp
assay
show
good
concord
k
ci
tabl
seen
archiv
specimen
howev
ftdrp
adv
rsv
rv
assay
gave
consist
lower
detect
rate
correspond
inhous
assay
respect
miss
specimen
high
viru
load
coincid
three
assay
combin
reaction
mix
mix
highest
codetect
rate
virus
inhous
assay
follow
mix
hbov
hmpv
mix
cov
cov
cov
evpev
mix
mix
inf
inf
b
simultan
presenc
multipl
target
specimen
may
led
competit
inhibit
amplif
less
abund
target
may
explain
loss
assay
sensit
ftdrp
hbov
assay
appear
sensit
correspond
inhous
assay
lu
et
al
specimen
contain
low
level
hbov
investig
find
limit
sequenc
studi
perform
use
newli
develop
seminest
pcr
assay
specif
hbov
gene
amplifi
recogn
hbov
type
protocol
avail
xl
upon
request
specimen
posit
hbov
inhous
ftdrp
assay
mean
inhous
ct
rang
success
sequenc
hbov
type
contrast
inhous
assay
posit
mean
ct
rang
ct
ftdrp
neg
none
ftdrp
posit
mean
ct
rang
ct
inhous
neg
specimen
could
confirm
pcr
sequenc
failur
resolv
discrep
may
due
higher
sensit
ftdrp
assay
specimen
contain
low
level
hbov
dna
possibl
attribut
larger
volum
tna
extract
use
ftdrp
assay
l
vs
l
ii
failur
assay
detect
variant
hbov
strain
andor
iii
nonspecif
amplif
amplicon
contamin
sampl
ftdrp
evpev
assay
also
appear
sensit
specif
correspond
inhous
ev
assay
specimen
specimen
posit
ftdrp
evpev
assay
mean
ct
rang
neg
inhous
ev
pev
assay
recover
andor
sequenc
repres
differ
ev
echoviru
enteroviru
polioviru
coxsackieviru
also
posit
inhous
ftdrp
rv
assay
ct
sequenceconfirm
speci
rv
also
typeindetermin
ev
sequenc
present
gave
fluoresc
amplif
curv
inhous
pev
assay
ct
valu
therefor
classifi
pev
neg
could
sequenc
sampl
posit
inhous
ev
assay
neg
ftdrp
evpev
assay
strongli
posit
rv
ct
inhous
ftdrp
rv
assay
confirm
posit
rv
speci
c
andor
sequenc
specimen
posit
inhous
tabl
comparison
ftdrp
inhous
assay
prospect
test
respiratori
specimen
inhous
ftdrp
inhous
diagnosi
ari
clinic
care
public
health
set
greatli
advanc
recent
year
increas
avail
rapid
sensit
specif
molecular
test
simultan
detect
multipl
respiratori
pathogen
commerci
assay
particular
receiv
fda
k
clearanc
made
substanti
inroad
diagnost
laboratori
rand
et
al
howev
assay
often
costli
requir
dedic
laboratori
equip
use
highli
multiplex
reaction
individu
assay
perform
may
compromis
difficult
modifi
quickli
respons
emerg
new
medic
import
viru
strain
occur
influenza
pandem
commerci
multiplex
ftdrp
realtim
rtpcr
assay
address
limit
offer
complet
kit
moder
throughput
detect
respiratori
virus
could
easili
integr
workflow
laboratori
use
convent
realtim
pcr
platform
ftdrp
assay
setup
runtim
requir
approxim
h
sampl
control
assay
reagent
aliquot
sampl
test
unit
exclud
sampl
extract
kit
list
price
pcr
enzym
kit
cost
includ
combin
assay
multiplex
reaction
mix
individu
mix
could
easili
modifi
need
without
impact
mix
could
allow
effici
target
test
base
epidemiolog
find
studi
ftdrp
multiplex
assay
compar
inhous
singleplex
assay
correspond
test
virus
overal
ftdrp
inhous
assay
perform
compar
virus
test
particularli
viru
abund
sampl
low
ct
valu
except
note
discord
result
seen
sampl
contain
lower
concentr
viru
high
ct
valu
suggest
differ
assay
sensit
near
detect
limit
respons
discrep
rather
failur
primerprob
hybrid
due
critic
target
sequenc
mismatch
ftdrp
assay
rsv
rv
adv
particular
show
lower
rel
sensit
correspond
inhous
assay
clinic
specimen
ftdrp
rv
assay
show
clear
evid
dropout
rv
strain
see
discuss
prospect
test
specimen
neg
rsv
adv
even
virus
abund
notabl
three
ftdrp
assay
combin
reaction
mix
three
virus
show
highest
codetect
rate
singleplex
inhous
specimen
possibl
compet
amplif
reaction
specimen
contain
multipl
viru
target
may
reduc
sensit
assay
low
abund
target
may
notic
impact
detect
adv
disproportion
number
adv
posit
specimen
lower
viru
load
would
expect
popul
compris
infant
young
children
persist
low
level
adv
shed
common
develop
realtim
rtpcr
assay
detect
rv
ev
strain
distinguish
group
challeng
due
extens
sequenc
divers
within
group
sequenc
similar
ev
rv
strain
data
confirm
previou
experi
inhous
ev
rv
assay
assay
crossreact
rv
ev
strain
particularli
present
high
copi
number
lu
et
al
oberst
et
al
although
complic
effort
evalu
ftdrp
evpev
rv
assay
sever
conclus
drawn
find
ftdrp
evpev
assay
appear
sensit
specif
inhous
assay
detect
ev
strain
includ
recent
emerg
cdc
although
crossreact
rv
strain
identifi
archiv
sampl
collect
could
rule
particular
concern
ftdrp
rv
assay
insensit
sequenc
confirm
rv
speci
b
c
strain
find
suggest
critic
primerprob
mismatch
virus
substanti
diminish
target
amplif
andor
probe
hybrid
extens
test
cultur
purifi
rv
ev
strain
necessari
assess
full
extent
defici
limit
discrep
test
conduct
focus
primarili
sampl
larg
differ
ct
valu
inhous
ftdrp
assay
resolv
discrep
result
assay
would
requir
extens
confirmatori
test
addit
molecular
test
possess
equal
greater
sensit
evalu
beyond
scope
studi
limit
specimen
volum
prevent
addit
test
case
appar
falseposit
result
either
assay
like
true
posit
occur
result
condit
note
follow
complet
work
fasttrack
diagnost
introduc
new
version
ftdrp
assay
ftd
respiratori
pathogen
expand
test
includ
new
respiratori
pathogen
modifi
exist
assay
enhanc
perform
miriam
steimer
fasttrack
diagnost
person
commun
given
chang
promis
potenti
ftdrp
multiplex
assay
diagnosi
respiratori
viru
infect
studi
expand
sampl
collect
warrant
